Clinical Trial Update: Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase I/II trial evaluating substituting nab-paclitaxel for either irinotecan or oxaliplatin in the FOLFIRINOX regimen as first-line treatment for m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Irinotecan (Camptosar) (Irinotecan)
• Nab-paclitaxel (Abraxane) (nab-paclitaxel)
• Oxaliplatin (Eloxatin) (oxaliplatin)

Snippet

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica | Conditions: Metastatic Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED